126273-59-4

Upstream product

• 126273-26-5 [3-(4-chloro-phenyl)-4-(4-fluoro-phenyl)-6-isopropyl-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-methanol 
• 64724-29-4 tributyl-((Z)-2-ethoxy-vinyl)-stannane 
• 126273-42-5 3-(4-chloro-phenyl)-4-(4-fluoro-phenyl)-6-isopropyl-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carbaldehyde 

Downstream Products

• 126273-74-3 7-[3-(4-chloro-phenyl)-4-(4-fluoro-phenyl)-6-isopropyl-1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-5-hydroxy-3-oxo-hept-6-enoic acid ethyl ester 

Relevant academic research and scientific papers

Synthesis and biological evaluations of condensed pyridine and condensed pyrimidine-based HMG-CoA reductase inhibitors

A series of 3,5-dihydroxyheptenoic acid derivatives containing pyrazolopyridine, isoxazolopyridine, thienopyridine, and pyrazolopyrimidine as a key scaffold was synthesized from condensed pyridine and condensed pyrimidine carboxylic acid esters by homologation, aldol condensation with ethyl acetoacetate dianion, and stereoselective reduction of the 5-hydroxyketone. Several compounds in the series were found to have potent HMG-CoA reductase inhibitory activities in vitro and marked cholesterol biosynthesis inhibitory activities in vivo. It has been shown that these scaffolds can be used as a suitable replacement for the hexahydronaphthalene ring present in naturally occurring HMG-CoA reductase inhibitors.